Here's a question I get more than almost any other: "Is Pfizer halal? What about J&J? They use pork gelatin in some of their capsules and vaccines, right?"

The short version is that Big Pharma is actually one of the more interesting screening cases in the stock market. Most of the major pharmaceutical companies pass Shariah screening, with caveats. The pork gelatin issue is real but smaller than people think. The bigger concerns are usually the financial ratios, and sometimes specific product lines.

Let's actually work through this properly because there's a lot of folk wisdom floating around that doesn't match how scholars actually rule on it.

The pork gelatin question, demystified

Gelatin is a protein derived from collagen in animal tissue. Historically, most pharmaceutical gelatin (for capsule shells, soft gels, and certain vaccine stabilizers) came from pork because pig skin is a cheap, plentiful source. Bovine gelatin exists. Fish gelatin exists. Plant-based alternatives (HPMC, pullulan) exist. But pork-derived gelatin is still common in Western pharma manufacturing.

The question is whether a pharma company using pork gelatin in some products automatically becomes non-compliant as a stock. This is where the scholarship gets nuanced.

The principle at play is istihalah (transformation). The classical jurists, including Imam Abu Hanifa, discussed cases where an impure substance undergoes enough chemical or physical transformation that it is no longer considered its original form. Wine that turns into vinegar is the classic example. It becomes halal because it's no longer wine in any meaningful sense.

Modern scholars including Shaykh Yusuf Al Qaradawi and the Islamic Fiqh Council of the Muslim World League have applied istihalah to pharmaceutical gelatin derived from pork. Their reasoning: the collagen has been chemically broken down, hydrolyzed, and recombined to the point that it no longer shares the chemical identity of pig tissue. Many (not all) scholars consider the final gelatin permissible under istihalah.

AAOIFI's Shariah Standards (standard 30 and 21) take a similar view for pharmaceutical and cosmetic ingredients that undergo substantial transformation, particularly when an alternative is not readily available.

Shaykh Taqi Usmani is more cautious on istihalah and has suggested that pork-derived gelatin should be avoided where alternatives exist, but even he doesn't rule that every Western pharmaceutical company is automatically non-compliant to invest in because of this.

Pfizer (NYSE: PFE) screening walkthrough

Let's actually run the numbers on Pfizer as of early 2026.

Core business: Research, development, manufacture, and sale of prescription drugs and vaccines. This is broadly permissible. Medicine is one of the most honored professions in Islamic tradition. Treating illness is a societal good.

Non-permissible income: Pfizer sells some products that involve pork-derived ingredients (certain capsule formulations, some vaccine stabilizers). The revenue from those specific products is typically a low single-digit percentage of total revenue. The 5 percent non-permissible income threshold is the relevant test. Pfizer generally passes this threshold.

Debt-to-market-cap: Here's where it gets dicey depending on the year. After the Seagen acquisition in 2023, Pfizer took on substantial debt. As of early 2026, long-term debt is around $57 billion. Market cap sits around $145 billion. That ratio is about 39 percent. Above the 30 percent threshold used by AAOIFI. Depending on which methodology you're following (some use trailing 24-month average market cap, which would change the denominator), Pfizer could be borderline or just above. This is a live issue.

Cash and interest-bearing securities: Pfizer holds roughly $18 billion in cash and short-term investments. Market cap around $145 billion. Ratio around 12 percent. Passes comfortably.

Accounts receivable: Around $12 billion. Ratio ~8 percent. Passes.

Result: Pfizer currently fails the debt ratio under AAOIFI methodology but passes it under some methodologies that use trailing averages. The pork gelatin question is not the main screening issue. The main issue is the balance sheet. Check the current figures before buying.

Johnson & Johnson (NYSE: JNJ)

J&J is a different beast. After the Kenvue spin-off in 2023, J&J is now a pure pharmaceutical and medical devices company. Much cleaner profile.

Core business: Prescription pharmaceuticals, biologics, medical devices, surgical equipment. All broadly permissible.

Non-permissible income: Small. J&J uses some porcine-derived components in surgical meshes and other products, but the revenue share is under the 5 percent threshold. Passes.

Debt-to-market-cap: Long-term debt around $30 billion against a market cap of ~$420 billion. Ratio about 7 percent. Passes easily.

Cash ratio: Around 6 percent. Passes.

Receivables: Around 4 percent. Passes.

Result: J&J currently passes Shariah screening under every major methodology. It's one of the cleanest large pharma names you can find.

Worth noting: JNJ was embroiled in the talc and opioid lawsuits, which raises its own ethical questions even if not strictly Shariah ones. Some Muslim investors apply a broader "avoid companies causing harm" filter. That's a separate conversation from screening.

Other major pharma names, scanned

Merck (MRK): Pharmaceuticals and vaccines. Passes sector. Debt-to-market-cap around 20 percent. Passes financial ratios. Clean.
Eli Lilly (LLY): Huge run thanks to GLP-1s. Market cap around $700 billion. Long-term debt around $34 billion. Ratio ~5 percent. Passes everything. Very clean.
AstraZeneca (AZN): Passes sector. Debt ratio around 22 percent. Passes financials.
Novartis (NVS): Swiss pharma giant. Passes sector. Debt ratio around 18 percent. Passes.
Roche (ROG.SW): Same story. Passes.
GlaxoSmithKline (GSK): Usually borderline on debt. As of early 2026, sits around 35 percent debt-to-market-cap. Fails AAOIFI but passes some other methodologies. Borderline.
Bristol-Myers Squibb (BMY): Debt issues from Celgene acquisition still lingering. Recent ratio around 40 percent. Fails debt screen under AAOIFI.
AbbVie (ABBV): Heavy debt load from Allergan. Debt-to-market-cap historically over 40 percent. Fails debt screen.
Sanofi (SNY): Debt ratio around 18 percent. Passes.

The pattern: the financial ratios (especially debt) are doing most of the work in rejecting pharma names. The pork gelatin question is almost never the deciding factor.

Contraception, abortifacients, and gene-editing

This is the other area where Muslim investors sometimes get stuck. Some pharmaceutical companies manufacture contraceptives, morning-after pills, or abortifacient drugs. How do scholars treat this?

Contraception itself is not prohibited in classical Islamic law under most interpretations. Temporary methods have been discussed by scholars for centuries without a general prohibition. Permanent sterilization raises more questions. Revenue from contraceptive products is generally not counted as non-compliant income by mainstream screening bodies.

Abortifacients are a different story. Scholars are divided, and the revenue share for any Big Pharma company from abortion-related products is so small it falls well under any tolerance threshold. Most screening methodologies don't flag it.

Gene editing and embryonic stem cell research raise ethical concerns that scholars are still working through. Again, the revenue share from these specific lines is small enough that screening methodologies don't usually reject the parent company on these grounds.

The vaccine question

During 2020 to 2022, a lot of Muslim investors started asking whether vaccine stocks were permissible given the use of porcine gelatin in some vaccine manufacturing processes and the use of human fetal cell lines in others.

The position adopted by the Indonesian Ulema Council (MUI), the Dar al-Ifta of Egypt, the UK's British Islamic Medical Association, and multiple Gulf fatwa councils was that vaccines are permissible where needed, including those with porcine-derived trace ingredients, under the principle of necessity and istihalah. This view is widely held but not universal.

For screening purposes: companies manufacturing vaccines are not flagged as non-compliant by mainstream Shariah indices. Moderna (MRNA), BioNTech (BNTX), Novavax (NVAX) all pass the sector screen. Their financial ratios are where they either pass or fail.

What about the opioid crisis?

If you're doing ethical investing in a broader sense, the opioid crisis is a genuine concern. Purdue Pharma (privately held, now dissolved), Johnson & Johnson, AbbVie (Allergan), Teva, and Mallinckrodt all faced major opioid litigation. Islamic ethics include a prohibition on causing harm to others (la darar wa la dirar). Some scholars have suggested that while this doesn't automatically render stocks non-compliant, conscientious investors might want to avoid companies with a demonstrated pattern of harmful products and concealment of risks.

That's a values call, not a screening one. The methodology doesn't automatically reject these companies.

The bottom line

Big Pharma is not the minefield some Muslims assume. The pork gelatin question is real but scholarly consensus (including AAOIFI and most contemporary scholars) treats pharmaceutical gelatin as permissible under istihalah when alternatives are unavailable, or as non-material for screening purposes when the revenue share is small.

The bigger issue in pharma screening is the balance sheet. Pfizer and AbbVie and Bristol-Myers Squibb are currently failing or borderline on the debt-to-market-cap ratio. J&J, Merck, Eli Lilly, Novartis, Roche, and AstraZeneca are passing comfortably.

Don't avoid pharma because you heard about pork gelatin. Check the financial ratios on the specific name you're looking at, because those are what's actually determining compliance. Run it through FaithScreener and you'll see the exact breakdown (sector, non-permissible income, debt ratio, cash ratio, receivables) updated with current figures. The answer is usually yes, with numbers that might surprise you.

Pharmaceutical Stocks: Pfizer, Johnson & Johnson, and the Pork Gelatin Question